Grid Computing Tackles Alzheimer's Disease

Technological advances have taken the medical world to a whole new level, as digital infrastructure and state-of-the-art software offer doctors and patients the right tools for diagnosis and treatment. Helping to advance the technology further is the NEUGRID (A grid-based e-infrastructure for data archiving/communication and computationally intensive applications in the medical sciences) project, which is backed with EUR 2.8 million in financial support under the 'Information and communication technologies' (ICT) Theme of the EU's Seventh Framework Programme (FP7).

The NEUGRID partners, who kick-started the project in 2008, are introducing a novel and user-friendly grid-based research e-Infrastructure that will give neuroscientists in Europe the support they need to tackle degenerative brain disorders including Alzheimer's disease.

In a nutshell, neuroscientists could use the grid-based research e-Infrastructure to identify neurodegenerative disease markers through the analysis of 3D (three-dimensional) magnetic resonance brain images thanks to a supply of distributed medical and grid services.

Experts say grid-computing is finding a solid niche in the medical world. "Grid-computing can help to create and improve tools facilitating drug development for chronic brain diseases," explained NEUGRID project leader Dr Giovanni B. Frisoni, who is the Vice Scientific Director of the San Giovanni di Dio Fatebenefratelli institute in Brescia, Italy, and head of the Neuroimaging Laboratory.

Commenting on the treatment Alzheimer's disease, a progressive form of dementia that destroys brain cells and triggers severe memory loss and problems with thinking and behaviour, Dr Frisoni said: "There is still no biomarker showing whether a drug works or not. Grid-computing can aim at developing markers which are based on images, such as the progressive cortical shrinking during ageing. This will allow [people] to monitor the progression of the disease and thus the effectiveness of a drug, significantly reducing the number of patients to be followed, on a shorter period of time."

It should be noted that the NEUGRID partners are ensuring data protection and the privacy of patients whose medical information is being used throughout the project. The partners say they are also maintaining ethical standards and data protection protocols in accordance with European emerging standards for grids in the health sector.

In the next 18 months, the partners will give clinical research institutes access to 3 crucial elements for their research into Alzheimer's disease. These institutes will also gain access to large databases worldwide.

The team is also diligently working on developing a mid-layer of services between user-facing and grid-facing services to help expand the infrastructure to various algorithm pipelines. The researchers are performing tests and validating the prototype infrastructure too.

The NEUGRID consortium has already participated in a number of dissemination workshops, conferences and congresses, and meetings. While the project draws to a close in January 2011, the NEUGRID partners say they plan to develop the services for other medical applications as well. NEUGRID brings together researchers and industry experts from France, Italy, the Netherlands, Spain, Sweden, Switzerland and the UK.

For further information, please visit:
http://www.neugrid.eu

Copyright ©European Communities, 2010
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Is AI in Medicine Playing Fair?

As artificial intelligence (AI) rapidly integrates into health care, a new study by researchers at the Icahn School of Medicine at Mount Sinai reveals that all generative AI models may...

Generative AI's Diagnostic Capabili…

The use of generative AI for diagnostics has attracted attention in the medical field and many research papers have been published on this topic. However, because the evaluation criteria were...

AI Tool can Track Effectiveness of Multi…

A new artificial intelligence (AI) tool that can help interpret and assess how well treatments are working for patients with multiple sclerosis (MS) has been developed by UCL researchers. AI uses...

New System for the Early Detection of Au…

A team from the Human-Tech Institute-Universitat Politècnica de València has developed a new system for the early detection of Autism Spectrum Disorder (ASD) using virtual reality and artificial intelligence. The...

Diagnoses and Treatment Recommendations …

A new study led by Prof. Dan Zeltzer, a digital health expert from the Berglas School of Economics at Tel Aviv University, compared the quality of diagnostic and treatment recommendations...

Dr Jason Broch Joins the Highland Market…

The Highland Marketing advisory board has welcomed a new member - Dr Jason Broch, a GP and director with a strong track record in the NHS and IT-enabled transformation. Dr Broch...

Surrey and Sussex Healthcare NHS Trust g…

Surrey and Sussex Healthcare NHS Trust has marked an important milestone in connecting busy radiologists across large parts of South East England, following the successful go live of Sectra's enterprise...

Multi-Resistance in Bacteria Predicted b…

An AI model trained on large amounts of genetic data can predict whether bacteria will become antibiotic-resistant. The new study shows that antibiotic resistance is more easily transmitted between genetically...

DMEA 2025 Ends with Record Attendance an…

8 - 10 April 2025, Berlin, Germany. DMEA 2025 came to a successful close with record attendance and an impressive program. 20,500 participants attended Europe's leading digital health event over the...